Factors of progression to severity and death in COVID-19 patients at two health care sites in Bamako, Mali.

Factors of progression to severity and death in COVID-19 patients at two health care sites in Bamako, Mali.

Publication date: Jan 17, 2025

To analyze the clinical and biological characteristics and to evaluate the risk factors associated with the mortality of patients with COVID-19 in Commune IV of the District of Bamako. The cohort consisted of COVID-19 patients managed from March 2020 to June 2022 at the Bamako Dermatology Hospital and the Pasteur Polyclinic in Commune IV in Bamako. The studied variables were sociodemographic, clinical, and biological. For the analysis of deaths, explanatory variables were grouped into sociodemographic factors, comorbidities and symptoms. Binomial logistic regression models were used to identify mortality associated risk factors. Among the 1319 included patients, 38. 4% were asymptomatic, 46% and 15. 5% developed moderate or severe COVID-19 respectively. The predominant signs were cough (48. 5%), respiratory difficulty (24. 6%) and headache (19. 7%). Male were more common (58. 2%). High blood pressure (19. 9%) and diabetes (10%) were the main comorbidities. D-dimers  60 years, high blood pressure, diabetes, clinical severity, D-dimers  60 years, increased heart rate, disease severity level and mainly acute respiratory distress syndrome (polypnea, difficulty breathing) were the factors found associated with death. After adjusting for all the assessed factors, age 

Open Access PDF

Concepts Keywords
Dermatology Adult
Diabetes Aged
Dimers60 Bamako
June Cohort Studies
Severe Comorbidity
COVID-19
COVID-19
Death
Disease Progression
Female
Humans
Male
Mali
Middle Aged
Risk Factors
SARS-CoV-2
Severity
Young Adult

Semantics

Type Source Name
disease MESH death
disease MESH COVID-19
disease MESH High blood pressure
disease MESH acute respiratory distress syndrome
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
drug DRUGBANK Azithromycin
disease MESH emergency
disease MESH influenza
disease MESH pharyngitis
disease MESH cough headache
disease MESH arthralgias
pathway REACTOME Immune System
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Ivermectin
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Fluvoxamine
disease IDO country
disease MESH anosmia
disease IDO history
disease MESH comorbidity
disease MESH lifestyles
drug DRUGBANK Creatinine
drug DRUGBANK Prothrombin
disease MESH pneumonia
disease MESH dyspnea
drug DRUGBANK Medical air
disease MESH septic shock
disease MESH contraindications
disease MESH thrombosis
drug DRUGBANK Dexamethasone
drug DRUGBANK Oxygen
drug DRUGBANK Zinc
drug DRUGBANK Acetaminophen
drug DRUGBANK Tocilizumab
drug DRUGBANK Sarilumab
disease MESH morbidities
disease MESH asthma
pathway KEGG Asthma
disease MESH malaria
pathway KEGG Malaria
disease MESH ageusia
disease IDO blood
disease MESH HIV infection
pathway REACTOME HIV Infection
disease MESH renal failure
disease MESH dysphagia
disease MESH Asymptomatic infection
disease MESH infection
disease MESH respiratory tract infection
disease MESH anorexia
disease MESH syndrome
disease MESH complications
disease IDO susceptibility
disease MESH non communicable diseases
disease MESH COPD
disease MESH malignancy
disease MESH abnormalities
drug DRUGBANK Trestolone
disease MESH critically ill
disease IDO reagent
drug DRUGBANK L-Citrulline
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Etoperidone
drug DRUGBANK Diethylstilbestrol
disease MESH severe acute respiratory syndrome
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Chloroquine
drug DRUGBANK Omacetaxine mepesuccinate
disease IDO replication
disease MESH Allergy
pathway REACTOME Innate Immune System
disease MESH Coronavirus infection
disease MESH acute kidney injury
disease MESH disseminated intravascular coagulation
disease MESH clinical course

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *